Single‐center off‐label benralizumab use for refractory hypereosinophilic syndrome demonstrates satisfactory safety and efficacy

Authors

Institutions

Publication Details

Journal
eJHaem
Published
2024-12-25
DOI
https://doi.org/10.1002/jha2.1014
Citations
2
Primary Topic
Eosinophilic Disorders and Syndromes
Type
article
Field-Weighted Citation Impact
0.94
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Single‐center off‐label benralizumab use for refractory hypereosinophilic syndrome demonstrates satisfactory safety and efficacy

Yvonne Veltman, Anna M. Aalbers, Pim G. N. J. Mutsaers, Maud A.W. Hermans
2 citations
eJHaem
Eosinophilic Disorders and Syndromes
0.94
article

Single‐center off‐label benralizumab use for refractory hypereosinophilic syndrome demonstrates satisfactory safety and efficacy

Yvonne Veltman, Anna M. Aalbers, Pim G. N. J. Mutsaers, Maud A.W. Hermans
article en
2 citations

Abstract

No abstract available for this paper.
eJHaemVol. 6(1)
Erasmus MC (NL)
Good health and well-being
Openalex Percentile: Top 21%
Eosinophilic Disorders and Syndromes
0.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Single‐center off‐label benralizumab use for refractory hypereosinophilic syndrome demonstrates satisfactory safety and efficacy — Yvonne Veltman, Anna M. Aalbers, et al. · eJHaem (2024) | TGRS Research Map | TGRS